Skip to main content
User account menu
Log in
Search
Main navigation
Home
Data Sources
Studies
Institutions
Networks
What's new
Support
Home
Johnson & Johnson
First published
01/02/2024
Last updated
01/02/2024
Institution
Download as PDF
Page content
Institution identification
Institution description
Institution details
Contact
Institution identification
PURI
https://redirect.ema.europa.eu/resource/3331386
Institution ID
3331386
Institution full name and acronym
Johnson & Johnson
ENCePP partner
No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No
Network(s) of which the institution is a member
id.DRIVE (former COVIDRIVE)
Data sources owned by the institution
This Institution does not have any datasource registered in the catalogue
Studies conducted by the institution
A Multi-Country Prospective Multi-Drug Resistant Tuberculosis Patient Registry to Monitor Bedaquiline Safety, Utilization, and Emergence of Resistance
A Post-Authorization Safety Study (PASS) to characterize the risk of secondary primary malignancy including MDS/AML among metastatic prostate cancer patients exposed to AKEEGA (niraparib/abiraterone acetate fixed-dose combination tablet) plus Prednisone/Prednisolone
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) (HALO)
A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis (OPAL)
Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study within US real world databases
Comparative safety study to assess the risk of anastomotic leakage of two-row versus three-row manual circular staplers in colorectal anastomosis
Comparing the Estimated Risk of Hip Fracture Among Subjects Exposed to Tramadol as Compared to Subjects Exposed to Codeine (Tramadol vs Codeine)
Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Below Knee Lower Extremity Amputation for Patients with Type 2 Diabetes Mellitus and the Subpopulation with Established Cardiovascular Disease
Exploring mediation through major bleeding between direct oral anticoagulants and cardiovascular events (MB mediation in CV RWE)
Incidence and risk of heart failure in patients following metal-on-metal (MoM) hip arthroplasty
Incidence and risk of Nail Breakage in patients implanted with the DePuy Synthes TFN-ADVANCED™ Proximal Femoral Nailing System (TFNA)
Incidence of Diabetic Ketoacidosis among Patients with Type 2 Diabetes Mellitus Treated with SGLT2 inhibitors or Other Antihyperglycemic Agents- A Retrospective, Observational, New-User Cohort Study Using 4 Administrative Claims Databases in the US
Meta-Analysis of Amputation Events from Clinical Trials DIA3008 (CANVAS), DIA4003 (CANVAS-R), and DNE3001 (CREDENCE)
Neuropsychiatric Adverse Events of Abiraterone Acetate and Enzalutamide: Meta-analysis of Randomized Clinical Trials with Real World Reporting Patterns from Eudravigilance
PCSCVM003617/ A Real-World Database Study of Canagliflozin Utilization in Type 1 Diabetes Patients Over Time among European Countries
Postauthorization Safety Study Survey to Evaluate the Effectiveness of the Ciltacabtagene Autoleucel HCP Educational Program and the Product Handling Training
Risk Factors for Aseptic Loosening after Primary Total Knee Arthroplasty with Cemented Knee Implants (Aseptic Loosening - Total Knee Arthroplasty)
RRA-21430: Acute Pancreatitis in Patients with Type 2 Diabetes Who are New Users of Canagliflozin as Compared with New Users of Other Antihyperglycemic Agents: A Retrospective Cohort Study Using Large Claims Databases in the United States
Survey to Assess the Effectiveness of SPRAVATO® Educational Materials for Additional Risk Minimization Measures in the European Union (PCSNSP002812)
Utilisation disease-modifying anti-rheumatic drugs (DMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study
Share this page